Advanced search
Publication Cover
Hematology Volume 18, 2013 - Issue 3
Submit an article Journal homepage
2,376
Views
14
CrossRef citations to date
0
Altmetric
CHRONIC MYELOID LEUKEMIA

Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance

Bahram ChahardouliDepartment of HematologySchool of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
,
Farhad ZakerDepartment of HematologySchool of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran; and Cellular and Molecular Research Center, Tehran University of Medical Sciences, Tehran, Iran
,
Seied Asadollah MousaviHematologyOncology, and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, IranCorrespondence[email protected]
,
Ahmad KazemiDepartment of HematologySchool of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
,
Mohammadreza OstadaliHematologyOncology, and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
,
Fatemeh NadaliDepartment of HematologySchool of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
,
Shahrbano RostamiHematologyOncology, and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
,
Kamran AlimoghaddamHematologyOncology, and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
&
Ardeshir GhavamzadeHematologyOncology, and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
 show all
Pages 158-162 | Published online: 18 Jul 2013

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Salvatore Perrone, Fulvio Massaro, Giuliana Alimena & Massimo Breccia. (2016) How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety. Expert Opinion on Pharmacotherapy 17:11, pages 1517-1526.
Read now

Articles from other publishers (13)

Omalbanin Mokhlesi, Mohammad Hadi Sadeghian, Arezoo Shajiei, Maryam Sheikhi, Payam Siyadat, Mohammad Mehdi Kooshyar, Hossein Rahimi, Nafiseh Amini, Maliheh Dadgar Moghadam, Hossein Ayatollahi, Seyyede Fatemeh Shams & Zahra Khoshnegah. (2023) Frequency of T315I Mutation in Patients with Chronic Myeloid Leukemia Before and During Imatinib Treatment: A Study in North-East of Iran. Journal of Advances in Medical and Biomedical Research 31:146, pages 244-249.
Crossref
Hao Zhang, Mingsheng Zhu, Mingzi Li, Duan Ni, Yuanhao Wang, Liping Deng, Kui Du, Shaoyong Lu, Hui Shi & Chen Cai. (2022) Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1. Frontiers in Pharmacology 13.
Crossref
Samya Dey, Soumi Basu, Shahena Shah, Debmalya Bhattacharyya, Partha Pratim Gupta, Mahasweta Acharjee, Susanta Roychoudhury & Somsubhra Nath. (2022) Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study. Cancer Treatment and Research Communications 33, pages 100635.
Crossref
Nazanin Heidari, Fatemeh Noroozi & Najmaldin Saki. (2021) High Expression of TWIST-1 in the Chronic Myeloid Leukemia Patients with T315I Mutation. Jentashapir Journal of Cellular and Molecular Biology 12:3.
Crossref
Muneerah A. H. Huwaikem, Gauthaman Kalamegam, Ghadeer Alrefaei, Farid Ahmed, Roaa Kadam, Talal Qadah, Khalid H. W. Sait & Peter N. Pushparaj. (2021) Human Wharton’s Jelly Stem Cell Secretions Inhibit Human Leukemic Cell Line K562 in vitro by Inducing Cell Cycle Arrest and Apoptosis. Frontiers in Cell and Developmental Biology 9.
Crossref
Mahboobeh Shojaei, Hamid Rezvani, Azita Azarkeivan & Behzad Poopak. (2021) ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors. Laboratory Medicine 52:2, pages 158-167.
Crossref
Reni Widyastuti, Melva Louisa, Ikhwan Rinaldi, Riki Nova, Instiaty Instiaty & Rizky Priambodo. (2020) Mutation Analysis of ABL1 Gene and its Relation to the Achievement of Major Molecular Response in Indonesian Chronic Myeloid Leukemia Patients. Current Pharmacogenomics and Personalized Medicine 17:1, pages 48-54.
Crossref
Erin Clapper, Sicong Wang, Prahlad V. Raninga, Giovanna Di Trapani & Kathryn F. Tonissen. (2020) Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment. Antioxidants 9:3, pages 207.
Crossref
Ladan Nekoohesh, Shahrbano Rostami, Mohsen Nikbakht, Saeed Mohammadi, Davood Babakhani, Kamran Alimoghaddam, Mohammad H. Ghahremani & Bahram Chahardouli. (2020) Evaluation of Molecular Response to Imatinib Mesylate Treatment in Iranian Patients With Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 20:1, pages e1-e10.
Crossref
Mohammed Sadeq Mahdi Al- Musawi, Raheem Mahdy Raheem, Liwaa Hussein Mahdi & Israa Ketab Al-Yasiri. (2019) Relation of common ABL kinase domain mutations with resistance to Tyrosine Kinase Inhibiters in patients with Chronic Myeloid Leukemia in Middle Euphrates of Iraq. Journal of Physics: Conference Series 1294:6, pages 062096.
Crossref
Jesus Paez-Mayorga, Andrew L. Chen, Sivareddy Kotla, Yunting Tao, Rei J. Abe, Emma D. He, Brian P. Danysh, Marie-Claude C. Hofmann & Nhat-Tu Le. (2018) Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation. Frontiers in Cardiovascular Medicine 5.
Crossref
Ellen Weisberg, Atsushi Nonami & James D. Griffin. (2014) Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies. Archives of Toxicology 88:12, pages 2233-2242.
Crossref
Yu-Qing Ge, Xiao-Feng Xu, Bo Yang, Zhe Chen & Ru-Bin Cheng. (2014) Saponins from Rubus parvifolius L. Induce Apoptosis in Human Chronic Myeloid Leukemia Cells through AMPK Activation and STAT3 Inhibition. Asian Pacific Journal of Cancer Prevention 15:13, pages 5455-5461.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.